• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Tivic Health Systems Inc.

    12/29/25 5:09:26 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $TIVC alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    Intentional misstatements or omissions of fact constitute federal criminal violations. See 18 U.S.C. 1001.

    FORM D

    Notice of Exempt Offering of Securities
    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
    X None
    Entity Type
    0001787740
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Tivic Health Systems, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Tivic Health Systems, Inc.
    Street Address 1 Street Address 2
    47685 LAKEVIEW BLVD
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    FREMONT CALIFORNIA 94538 888-276-6888

    3. Related Persons

    Last Name First Name Middle Name
    Ernst Jennifer
    Street Address 1 Street Address 2
    47685 Lakeview Blvd.
    City State/Province/Country ZIP/PostalCode
    Fremont CALIFORNIA 94538
    Relationship: X Executive Officer X Director X Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Bolton Sheryle
    Street Address 1 Street Address 2
    47685 Lakeview Blvd.
    City State/Province/Country ZIP/PostalCode
    Fremont CALIFORNIA 94538
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Valauri Christina
    Street Address 1 Street Address 2
    47685 Lakeview Blvd.
    City State/Province/Country ZIP/PostalCode
    Fremont CALIFORNIA 94538
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Zikria Dean
    Street Address 1 Street Address 2
    47685 Lakeview Blvd.
    City State/Province/Country ZIP/PostalCode
    Fremont CALIFORNIA 94538
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Wolf Lisa
    Street Address 1 Street Address 2
    47685 Lakeview Blvd.
    City State/Province/Country ZIP/PostalCode
    Fremont CALIFORNIA 94538
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Handley Michael
    Street Address 1 Street Address 2
    47685 Lakeview Blvd.
    City State/Province/Country ZIP/PostalCode
    Fremont CALIFORNIA 94538
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-12-10    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
    X Yes    No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
    X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $75,000,000 USD
    or    Indefinite
    Total Amount Sold $12,000,000 USD
    Total Remaining to be Sold $63,000,000 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    Securities include preferred stock and warrants.

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    5

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Tivic Health Systems, Inc. /s/ Jennifer Ernst Jennifer Ernst Chief Executive Officer 2025-12-29

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $TIVC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TIVC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TIVC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tivic Expands Intellectual Property Portfolio

    New Biologics Patent Application Covers Potential Applicability of TLR5 Agonists to Improve Outcomes for Late-stage Cancer Therapies; Bioelectronic Patent Covers Optimized ncVNS Device Specifications Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, today announced it is expanding its intellectual property portfolio with the recent filing of two additional patent applications with the United States Patent and Trademark Office. The first application applies to Tivic's TLR5 agonist portfolio, which includes Entolimod and Entolasta. The patent titled "Immunomodulatory Pathway Modifying Agents and Uses of Same for Cancer Therapy" relates to the potential newly i

    11/10/25 9:00:00 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that it will report its third quarter results for 2025 via pre-recorded conference call and webcast on Friday, November 14, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 230582 Webcast Link https://www.webcaster5.com/Webcast/Page/2865/53145 About Tivic Health Systems, Inc. Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell

    11/6/25 9:30:00 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine. When: Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT Panel Title: Building a Big Tent Bioelectronic Medicine stands to disrupt how we diagnose, treat, and manage disease, but fulfilling that promise requires broad alignment across the healthcare ecosystem. This session will explore how to rally the global community,

    10/22/25 2:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $TIVC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Wolf Lisa G converted options into 736 shares and covered exercise/tax liability with 302 shares (SEC Form 4)

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    12/22/25 8:45:14 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Executive Officer Ernst Jennifer converted options into 14,706 shares and covered exercise/tax liability with 5,262 shares, increasing direct ownership by 41% to 32,691 units (SEC Form 4)

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    12/22/25 8:44:46 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Executive Officer Ernst Jennifer was granted 22,541 shares, increasing direct ownership by 3,193% to 23,247 units (SEC Form 4)

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    9/24/25 8:02:15 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $TIVC
    SEC Filings

    View All

    SEC Form DEF 14A filed by Tivic Health Systems Inc.

    DEF 14A - Tivic Health Systems, Inc. (0001787740) (Filer)

    1/9/26 4:31:09 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form D filed by Tivic Health Systems Inc.

    D - Tivic Health Systems, Inc. (0001787740) (Filer)

    12/29/25 5:09:26 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form D filed by Tivic Health Systems Inc.

    D - Tivic Health Systems, Inc. (0001787740) (Filer)

    12/29/25 5:09:03 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $TIVC
    Financials

    Live finance-specific insights

    View All

    Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that it will report its third quarter results for 2025 via pre-recorded conference call and webcast on Friday, November 14, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 230582 Webcast Link https://www.webcaster5.com/Webcast/Page/2865/53145 About Tivic Health Systems, Inc. Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell

    11/6/25 9:30:00 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tivic Reports Second Quarter 2025 Financial Results

    Company advances its TLR5 agonist program and prepares to report VNS clinical data Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced financial results for the second quarter and six months ended June 30, 2025. "We have established a strong foundation for Tivic's strategic transformation with our expansion into biopharmaceuticals, making us unique in treating disease by addressing both the body's biochemical and bioelectronic systems," stated Tivic CEO Jennifer Ernst. "To maximize our focus on the compelling, late-stage clinical pipeline, we have increasingly shifted resources away from consumer healthtech and are now planning to exit

    8/14/25 4:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tivic Health to Report Second Quarter 2025 Financial Results on August 14th Via Conference Call and Webcast

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today announced that it will report its second quarter results for 2025 via pre-recorded conference call and webcast on Thursday, August 14, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 793820 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/52776 About Tivic Health Systems, Inc. Tivic Health seeks to treat underserved medical conditions through biochemical and bioelectric therapies that modulate patients' immune system. The company's

    8/7/25 8:30:00 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $TIVC
    Leadership Updates

    Live Leadership Updates

    View All

    Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine. When: Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT Panel Title: Building a Big Tent Bioelectronic Medicine stands to disrupt how we diagnose, treat, and manage disease, but fulfilling that promise requires broad alignment across the healthcare ecosystem. This session will explore how to rally the global community,

    10/22/25 2:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team

    Handley Joins as President of Tivic Biopharma and Chief Operating Officer of Tivic Health Following Its Licensing of Strategic Biopharma Assets From Statera Biopharma Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma, Inc., has joined Tivic Health as the President of Tivic Biopharma, a newly formed division of Tivic Health. Additionally, he will assume the role of Chief Operating Officer of Tivic Health and will work closely with the CEO and other leadership team members to develop and operationalize company-wide strategies. His key responsi

    2/24/25 8:15:00 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tivic Health Appoints Lisa Wolf as Interim Chief Financial Officer

    Kimberly Bambach, Ms. Wolf's predecessor, continues with Tivic as advisor focused on strategic transactions and special projects Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to announce the appointment of Lisa Wolf as Interim Chief Financial Officer (CFO) of the company, effective October 1, 2024. Ms. Wolf will take over from Kimberly Bambach, who has served as the company's interim CFO since April 2023. Ms. Bambach will continue with Tivic in an advisory role for strategic transactions and other special projects. "Lisa has served as a senior member of Tivic's finance team for over two

    9/13/24 5:29:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $TIVC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tivic Health Systems Inc.

    SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

    5/15/24 4:47:23 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Tivic Health Systems Inc. (Amendment)

    SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

    2/9/24 4:05:08 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Tivic Health Systems Inc. (Amendment)

    SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

    2/1/24 9:01:29 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care